The Therapeutic Approach for Malignant Melanoma: Case 2
The Therapeutic Approach for Malignant Melanoma
April 2017
- A 52-year-old female presented to her dermatologist with a pigmented lesion which had recently become darker; she had it removed for cosmetic reasons
- Pathology revealed a melanoma with a depth of 2.3 mm
- Genetic testing;BRAF V600mutation-positive
- LDH, WNL (174 UI/L)
- She underwent wide local excision and sentinel node mapping; staining is positive for melanoma in the right axillary node
- Complete dissection of the right axilla reveals no additional involved nodes
- CT of the chest, abdomen, and pelvis showed multiple masses in both lungs, the largest being 5 mm
- She underwent core-needle biopsy of the largest lung lesion
- Pathology revealed metastatic melanoma
- Mutation testing:BRAF-positive
- The patient is started on dabrafenib 150 mg bid and trametinib 2 mg qd
Related Videos
Related Content
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024Article
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024Article
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More
